Tag: Clinical Trials
Many Ineligible for Clinical Trial Could Benefit From Teclistamab for Multiple Myeloma
89 percent of 509 patients would have been ineligible for MajesTEC-1 trial; estimated median PFS was 5.8 months
Approved-Label Populations for New Drugs Broader Than Trial Populations
Inconsistency seen most often in terms of patient fitness, with variance in almost all approved indications
Shorter-Form Messaging May Be Preferable for Trial Recruitment
Enrollment in DANFLU-2 trial was significantly more likely for those receiving single-page letter versus two-page letters
NIH Research Cuts Leave Cancer Patient Facing Hard Choice
Semaglutide May Reduce Craving in Alcohol Use Disorder
Phase 2 trial shows significant reduction in drinks per drinking day and weekly alcohol craving
One in Six Patients in Phase 2 Cancer Trials Receive Drug When Eventually Approved
Proportion increases when considering off-label use but drops when considering drugs with substantial clinical benefit
AI-Assisted Screening Tool Speeds Trial Eligibility Determination
Implementing AI-assisted screening tool enhances clinical trial efficiency, expedites screening process
Tecovirimat No Aid for Time to Lesion Resolution With Mpox
Additionally, interim analysis shows that the antiviral is safe but has no effect on pain among adults with mild-to-moderate clade II mpox
About One-Third Eligible for Weight Loss Drugs Meet Trial Exclusion Criteria
Most common exclusion criteria were major depressive disorder, malignant neoplasms, liver disease, uncontrolled HTN
Progression-Free Survival Improved With Nivolumab + AVD in Hodgkin Lymphoma
Longer progression-free survival seen with nivolumab + doxorubicin, vinblastine, and dacarbazine (AVD) versus brentuximab vedotin + AVD
